免疫磁珠富集联合新一代流式细胞术超敏检测循环多发性骨髓瘤细胞
本研究提出BloodFlow方法,将外周血CD138+循环浆细胞免疫磁珠富集与新一代流式细胞术(NGF)结合,用于检测低于2×10⁻⁶ NGF阈值的周围残留病(PRD)。在295例患者的644份外周血样本中,BloodFlow检出55份(8.5%)PRD,最低检出限为6×10⁻⁸,以骨髓可测量残留病(MRD)为参考的阳性预测值和阴性预测值分别为95.1%和76.6%。维持或观察期间可检测到PRD预示无进展生存期(PFS)和总生存期较差(2年率分别为0%和62%)。
要点
- BloodFlow在644份外周血样本中检出55份(8.5%)PRD,最低检出限6×10⁻⁸。
- 52.7%外周血样本BloodFlow阳性而NGF阴性,以骨髓MRD为参考阳性预测值95.1%、阴性预测值76.6%。
- 维持或观察期间可检测到PRD预示PFS和OS较差,2年率分别为0%和62%。
核心结论
- BloodFlow是首个检测低于10⁻⁶阈值肿瘤细胞的流式细胞术方法,可改善多发性骨髓瘤患者的微创监测。
研究设计与样本
- 本研究为方法学研究,将外周血CD138+循环浆细胞免疫磁珠富集与新一代流式细胞术(NGF)结合,检测295例多发性骨髓瘤患者的外周血周围残留病(PRD)。
主要发现
- BloodFlow在644份外周血样本中检出55份(8.5%)PRD,最低检出PRD为6×10⁻⁸。
- 52.7%外周血样本BloodFlow阳性而NGF阴性。
- 以骨髓可测量残留病(MRD)状态为参考,BloodFlow阳性预测值为95.1%,阴性预测值为76.6%。
- 维持或观察期间可检测到PRD预示无进展生存期和总生存期较差,2年率分别为0%和62%。
- 多因素分析中,BloodFlow在外周血中优于NGF,并对PFS保留独立预后价值,分析因素包括移植资格、修订版国际分期系统、完全缓解和MRD状态。
关键数值与推荐
- BloodFlow检测PRD的阈值低于2×10⁻⁶ NGF阈值,最低检出PRD为6×10⁻⁸。
- 以骨髓MRD为参考,BloodFlow阳性预测值95.1%,阴性预测值76.6%。
- 维持或观察期间可检测到PRD者2年PFS率为0%,2年OS率为62%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The continuous improvement in progression-free survival (PFS) of patients with multiple myeloma (MM) raises interest in evaluating peripheral residual disease (PRD) toward more frequent readouts of tumor kinetics while preserving quality of life. We present BloodFlow, a new method combining immunomagnetic enrichment of CD138+ circulating plasma cells in peripheral blood (PB) with next-generation flow (NGF), for the detection of PRD below the 2 × 10-6 NGF threshold. BloodFlow detected PRD in 55 of 644 PB samples (8.5%) from 295 patients. Of note, 52.7% PB samples were positive using BloodFlow and negative by NGF. The lowest PRD detected by BloodFlow was 6 × 10-8. Using bone marrow measurable residual disease (MRD) status as the reference, BloodFlow showed positive and negative predictive values of 95.1% and 76.6%, respectively. Detectable PRD during maintenance or observation predicted dismal PFS and overall survival (2-year rates of 0% and 62%, respectively). BloodFlow surpassed NGF in PB and retained independent prognostic value for PFS in multivariate analysis, including transplant eligibility, the revised International Staging System, complete remission, and MRD status. BloodFlow is the first flow cytometry method that detects tumor cells below the 10-6 threshold, enabling improved minimally invasive monitoring of patients with MM.
引用
- Lasa M, Gonzalez C, Notarfranchi L, et al. Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment. Blood. 2025. PMID: 40403320. doi:10.1182/blood.2025029234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。